A cancer diagnosis is overwhelming — especially far from home. UFH’s oncology service brings together surgeons, medical oncologists, radiologists and pathologists in a multidisciplinary tumor board, so your case is reviewed collectively and your plan is clear before treatment begins.

How We Care for You

  • Multidisciplinary tumor board — specialists review your case together and agree on a coordinated plan.
  • Advanced diagnostics — imaging, laboratory and pathology supporting accurate staging.
  • Treatment coordination — surgery, systemic therapy and radiotherapy planned and scheduled without duplication.
  • Second opinions — we welcome patients seeking clarity on a previous diagnosis or plan.
  • Supportive care — nutrition, pain management and emotional support throughout.
A note on approach. UFH delivers evidence-based oncology within its hospital network. For the most advanced or trial-based therapies, our team coordinates referrals and continuity of care with you and your home physician.

For International Patients

Begin with a remote consultation: share your pathology and imaging, and our team will provide a preliminary assessment and a proposed plan — so you can make informed decisions before traveling to China.

Coordinated, Compassionate, Clear

🧮

Team-Based

One plan, agreed by all your specialists — no contradictory advice.

💬

Understood

Every stage explained in English, with interpreters when needed.

💖

Supported

A care coordinator walks with you from diagnosis through follow-up.

Speak With Our Oncology Team

Share your reports for a remote second opinion and treatment plan.

Request Consultation Remote Second Opinion

Latest: Beizray — Tween-80-Free Docetaxel — Now at UFH Guangzhou

Through the HK–Macau Drugs & Devices channel, Guangzhou United Family Hospital is the first UFH campus to introduce Beizray®, a novel albumin-bound docetaxel for breast, lung, head-and-neck, gastric, prostate and gynecologic cancers — with Grade 3/4 haematological toxicity of 2.3% vs 15.9% for traditional docetaxel.

Read the clinical evidence →